UK CROs to Unveil Collaboration at Nordic Event
Several UK-based contract research organisations (CROs) will head to Denmark next week to present how collaborative outsourcing can help drug development companies overcome R&D scientific challenges.
Supported by the UK Trade & Investment (UKTI) the conference, entitled 'The Changing Face of Pharmaceutical Discovery and Development — A Collaborative CRO Approach', will give life science research companies from across the Nordic region the opportunity to converse with CROs and understand the value of a joint supply chain.
Guest speakers include Dr Daniel Greve from Leo Pharma and Dr Richard Weaver from XenoGesis along with CRO snapshots from companies in attendance, covering drug discovery activities and product development. These include Molecular Profiles, Charnwood Molecular, Aurelia BioScience, Reach Separations and Biopta.
The presentations, which will be hosted at the residence of the British Ambassador in Copenhagen on the 25 March 2015, will have a specific focus on drug discovery and development in Scandinavia.
Commenting on the discussion, Dr Richard Weaver, managing director at XenoGesis said: “Attracting new business is essential to our success. By having this collaborative approach and offering a comprehensive range of drug discovery activities, we are confident in providing an attractive proposition to Nordic countries seeking support with their research projects.
“Clients recognise the value of specialist expertise and appreciate the quality and turnaround speed that dedicated organisations can provide.”
Aimed at R&D scientists, project leaders and resource managers, the meeting will also reflect on current trends in outsourcing worldwide The UK companies attending complement each other in their drug discovery activities and product development.
Aurelia BioScience covers compound screening to identify hit and lead molecules, while organic synthesis is covered by Charnwood Molecular. XenoGesis meanwhile is a specialist in drug metabolism and pharmacokinetics (DMPK) testing. Reach Separations provides the analytical and chromatographic expertise, particularly for chiral compounds.
Molecular Profiles provides pharmaceutical development services and clinical trial manufacturing for small molecules and can work from early phase development to late stage clinical manufacture. Biopta addresses the issue of translational relevance, proving data from tailored fresh human tissue assay systems; interfacing with the other groups by testing novel molecules for efficacy, absorption or safety in healthy and diseased tissue.
Peter Ridgway, director at Reach Separations, added: “We have a strong understanding of each others capabilities and how we can work together effectively to become more competitive.
“As companies become more confident with outsourcing, the way they approach it is evolving. The need for a collaborative approach of bringing services together in this way is only going to grow.”
UKTI international trade adviser, Louise Stock, who has provided advice and support in arranging the market visit, added: “UKTI East Midlands is delighted to support the Nottingham based companies. The companies have been able to access funding from UKTI and we have further assisted them in identifying other sources of funding to support the market visit.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance